.
MergerLinks Header Logo

Announced

Completed

The Column Group led a $148m Series A round in Eikon Therapeutics.

Financials

Edit Data
Transaction Value£106m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Private Equity

Domestic

Single Bidder

drug discovery

biopharmaceutical company

Acquisition

Completed

Biotechnology

Venture Capital

Friendly

Private

Minority

Synopsis

Edit

The Column Group, a private equity firm, led a $148m Series A funding round in Eikon Therapeutics, a biopharmaceutical and drug research company. Additional investors include Foresite Capital, Innovation Endeavors and Lux Capital. “Roger shares this passion for integrative science and building high-performing R&D organizations where diverse skill sets are honored and encouraged. On behalf of the entire team, we look forward to working with him to continue building an organization of interdisciplinary experts who share our commitment to developing new therapies for severe unmet health needs," Leon Chen, The Column Group Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US